Q1 2020 Results Slides

Issue link: https://liminalbiosciences.com/resources/i/1247103

Contents of this Issue


Page 10 of 11

© 2020 Liminal BioSciences Inc. In March 2020, a significant portion of our workforce transitioned to working remotely Production facilities continue to operate, and preparing for FDA review of Ryplazim ® BLA and plant inspection R&D laboratories continue to operate and progressing fezagepras and GPR84 antagonist program Business Continuity Alström Phase 2 rollover study: Treatment terminated; publication of data in progress Phase 1 MAD study of fezagepras in UK to be initiated in 2020 Small Molecules Resubmission of BLA for Ryplazim ® Continue to explore alternatives for marketing of Ryplazim ® in US, if approval granted by FDA Plasma collection centers continue to operate with social distancing measures and have begun collecting plasma from recovered COVID-19 patients Plasma Business Update 11

Articles in this issue

view archives of Webcasts - Q1 2020 Results Slides